Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Last year, scientists released the results from the first genetic analysis of the STAR*D trial. They found that people with a specific variation in a receptor for the chemical messenger serotonin were more likely to respond to citalopram, an antidepressant that targets the serotonin system. Scientists are now analyzing the DNA of patients in the study who responded to different classes of antidepressants. “We want to determine ifgenetic makeup can tell us which medications are good or bad for individual patients,” says A. John Rush, a psychiatrist at the University of Texas Southwestern Medical Center, in Dallas, who is leading the STAR*D trial.

A similar trial for bipolar disorder, called the STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder) trial, wrapped up this month, and scientists are running similar genetic studies in search of the genetic roots of this disease. Both groups are focusing on specific regions of the genome that have previously been linked to the disorders, as well as using newer genomics technology–DNA microarrays that can analyze thousands of genetic variations in a single experiment–to scan the entire genome for clues. Scientists say that they expect to publish results within the next few months.

The findings might ultimately help psychiatrists redefine these complex disorders. For example, patients diagnosed with depression can have very different symptoms, and many symptoms are common to both depression and bipolar disorders. “We have diagnosis of mood disorders and other psychiatric disorders, but it’s not entirely clear if genes are influencing these disorders per se, or if they influence specific symptoms that cut across diagnostic categories,” says Smoller. “Genetic studies may tell us something about how we understand the relationships between different disorders.”

8 comments. Share your thoughts »

Credit: National Gallery, Oslo

Tagged: Biomedicine, genetics, drugs, mental health

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me